Shionogi Announces U.S. Government Procurement of Fetroja® (cefiderocol) Through BARDA's Project BioShield to Support National Preparedness for Drug-Resistant Bacterial Threats

OSAKA, Japan--(BUSINESS WIRE)--Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter "Shionogi") announced that the Biomedical Advanced Research and Development Authority (BARDA) has exercised a $36.9 million procurement option, under Project BioShield funding, from its April 2026 contract with Shionogi Inc., a New Jersey-based subsidiary of Shionogi, to procure Fetroja® (cefiderocol) as a critical countermeasure against difficult-to-trea